Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos, a discoverer and developer of small molecule and antibody therapies with novel modes-of-action, has decided to terminate the GLPG0259 Phase II clinical trial in rheumatoid arthritis (RA).
Subscribe to our email newsletter
The company’s decision is based on an interim analysis data, which according to the members of the Interim Review Committee does not support the continuation of GLPG0259’s development as a treatment for rheumatoid arthritis.
Additionally, the committee has also revealed that the compound has demonstrated limited efficacy in the Phase II trial.
However, Galapagos plans to conclude a full analysis of the data before coming to any conclusion related to the Phase II trial.
Galapagos CEO Onno van de Stolpe said the innovative trial design used in this Phase II trial enabled quick determination regarding GLPG0259’s potential efficacy in RA.
"Galapagos remains on- track to deliver the remainder of its operational objectives in 2011 as well as meet full year financial guidance of at least EUR150m in revenues, profitability and positive cash flow in 2011," Stolpe said.